Aims -We previously demonstrated that solid drug nanoparticles (SDNs) lopinavir dispersed into 17 aqueous media display favourable pharmacokinetics. 18
whereas lopinavir SDNs did not elicit these responses at comparable drug concentrations. Lopinavir 23
SDNs were demonstrated to be immunologically inert to human T cells and monocyte-derived 24
macrophages. 25
Conclusion -The lopinavir SDN was demonstrated to exhibit comparable, or favourable behaviour 26 compared to a lopinavir aqueous solution in the employed biocompatibility assessments. 27
28

INTRODUCTION 30
Antiretroviral therapy has significantly improved the morbidity and mortality associated with HIV 31 infection, but an estimated 20-30% of patients initiating therapy still discontinue treatment within 32 two years, the majority being toxicity related but also a significant number due to virological failure 33
[1]. Toxicity and drug failure are costly as toxicity results in significant morbidity and subsequent 34 regimens are associated with higher pill burden and a higher expensive to healthcare providers. The 35 introduction of HIV protease inhibitors (PIs) in the 1990s, significantly reduced morbidity and 36 mortality and prolonged the lifespan of patients [2] . However, there are a number of side effects 37 associated with these drugs such as; dyslipidaemia, insulin resistance, lipodystrophy and 38 hepatotoxicity [2] [3] [4] [5] . Although the underlying mechanisms of these side effects is yet to be fully 39 elucidated, a number of possibilities have been demonstrated such as; induction of IL-6 and TNFα 40 secretion [6] , activation of the unfolded protein response [7] , impairment of protein synthesis and 41 activation of AMP-activated protein kinase (AMPK) [8] . PIs also exhibit incomplete absorption and 42 rapid systemic clearance, resulting in a requirement for pharmacoenhancement by co-43 administration of ritonavir or cobicistat as a pharmacokinetic "booster". Despite 44 pharmacoenhancement, pharmacokinetics are highly variable within populations and the class has 45 attracted interest by many investigators exploring nanotechnology-enabled drug delivery [9] [10] [11] . 46 47 Many nanomaterials platforms are being investigated for their potential to augment drug delivery. 48
Unlike nanocarrier systems (e.g. lipid-based, polymer-based or inorganic materials), solid drug 49 nanoparticles (SDNs) rely upon advanced formulation tools to generate nanoparticles that are 50 composed of the drug itself. To date, the most commercially successful SDN manufacturing platform 51 has been provided by nanomilling technologies [12] . The overwhelming majority of SDN 52 formulations have been developed for oral dosing and are thought to release drug prior to 53 absorption such that particulates do not enter the systemic circulation. However, recent work has 54
MACSiBead particles (2.5 x 10 6 ) were added to a sterile universal tube with complete culture media 121 (RPMI-1640, 10% FCS). MACSiBead particles were then centrifuged (450xg) for 5 minutes, the 122 supernatant fraction was removed and the MACSiBeads were resuspended in complete culture 123 media (RPMI-1640, 10% FCS). PBMC densities were adjusted to 5 x 10 6 cells per mL. PBMC and 124
MACSiBeads preparations were then combined and incubated in a humidified incubator, at 37°C for 125 24 hours. In addition to untreated controls and MACSiBead positive controls, PBMC were treated 126 with lopinavir aqueous solution (10µM) or lopinavir SDNs (10µM) to assess potential for lymphocyte 127 activation. Additionally, PBMC were co-cultured with MACSiBead particles and lopinavir aqueous 128 Cytochalasin B (10µM, Sigma, UK)). Culture media was aspirated from each well and replaced with 184 the pHrodo bioparticle solution. The plate was covered and transferred to an incubator at 37°C 185 without CO 2 to prevent artificial acidification of the uptake buffer thereby minimising background 186 signal. Plates were read using a plate reader with an excitation of 550nm and emission of 600nm. 187
Statistical analysis 188
Distribution of the data was assessed using a Shapiro-Wilk test. For comparisons between datasets 189 either an unpaired t-test or a Mann-Whitney test was used for normally and non-normally 190 distributed data respectively. Stats Direct software (version 3.0.171) was used for data analysis and a 191 P value < 0.05 was considered statistically significant. 192
RESULTS 193
Physical characteristics of lopinavir solid drug nanoparticles we assessed the impact of these nanoparticles on T cell and macrophage function 408
Results
409
 Endotoxin was present in the studied formulations however; it was present at very low 410 levels unlikely to induce an immunological response. 
